Spruce Biosciences, Inc. (SPRB) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial.
Spruce Biosciences, Inc. Fundamental Analysis
Price to Book (PBV) Ratio
Undervalued price-to-book. SPRB stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER)
SPRB equity is higher than it's debt.
Small market capitalization. Market capitalization is less than 2bn USD
SPRB has never had growing revenue.
Net Income Growth
SPRB has never had growing net income.
SPRB never has positive net income for 2 years.
SPRB has low dividend yield (0%).
Return of Assets
SPRB has low return of asset (-46.4%).
Return of Equity
SPRB has low return of equity (-46.64%).
SPRB never has positive revenue for 2 years.
Return of Invested Capital
SPRB has low ROIC.
Spruce Biosciences, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 0 USD
- 0 USD
- Net Income
- -42,292,000 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -35,970,000 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||-0.6x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||21.44%|
|Net Profit Margin (NPM)||0%|
|Return of Assets (ROA)||-46.4%|
|Return of Equity (ROE)||-46.64%|
|Return on Capital Employed (ROCE)||-53.19%|
|Days of Sales Outstanding (DSO)||0|
|Days of Inventory Outstanding (DIO)||0|
|Days Payable Outstanding (DPO)||0|
|Operating Cycle (OC)||0|
|Cash Conversion Cycle (CCC)||0|
Spruce Biosciences, Inc. Executives
- CEO Name
- Mr. Michael G. Grey
Spruce Biosciences, Inc. Profile
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
- Company name
- Spruce Biosciences, Inc.
- NASDAQ Global Select
2001 Junipero Serra Boulevard